You are here:
Pediatricians and computer scientists join forces at the Helmholtz Munich Institute for Diabetes Research to identify children with type 1 diabetes before they develop symptoms. With the help of advanced statistics and machine learning, the…
The increasing amount of patients with obesity and type 2 diabetes benefit greatly from the recently developed GIPR:GLP-1R co-agonists. These novel compounds lead to substantial weight loss, offering a revolutionary approach to patients worldwide.…
The Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of Helmholtz Munich, located in Leipzig, is part of the SPIN2030 initiative.
In a groundbreaking collaborative effort, academic researchers, industry leaders, and charities have joined forces to combat Type 1 Diabetes (T1D) with the support of a €22 million grant from the Innovative Health Initiative (IHI). EDENT1FI, which…
Heinrich Wieland Prize for Matthias Tschöp: Breakthrough in the battle against obesity and diabetes
Prof. Matthias Tschöp explains why multi-receptor drugs are game changers in treating obesity and preventing diabetes effectively and safely – and why they are not a “miracle treatment” for a dream body. This year, he received the Banting Medal for…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
